Study registration: *
Publication Corchado-Garcia J, medRxiv, 2021
Dates: 2021-02-27 to 2021-04-14
Funding: No specific funding (No external funding was received for this study)
Conflict of interest: Yes (JCO receives personal fees from Elsevier and Bates College, and receives small grants from nference, Inc, outside the submitted work. ADB is a consultant for Abbvie, is on scientific advisory boards for nference and Zentalis, and is founder and President of Splissen therapeutics. The Mayo Clinic may and other bio-pharmaceutical companies on data science initiatives unrelated to this study.)

Methods

Study design:Cohort
Description of participants: Adults who underwent SARS-CoV-2 polymerase chain reaction (PCR) testing in multiple centers in USA
Inclusion criteria:
  • Underwent at least one SARS-CoV-2 polymerase chain reaction (PCR) test at the Mayo Clinic Health system in 2020-2021
  • at least 18 years old
  • resides in a local (based on Zip code) in which at least 10 patients who have received the Ad26.COV2.S vaccine.

Exclusion criteria:
  • Positive SARS-CoV-2 PCR test before the date of vaccine administration or the beginning of the study period (Feb 27, 2021)
  • individuals with zero followup days after vaccination (i.e. those who received the vaccine dose on the last date of data collection)
  • individuals vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech) and
  • no research authorization on file.

Follow-up duration (months): 1.51
Vaccines:
  • 1 dose of Ad26.COV2.S
Variant description :
Variant name: Alpha
Evidence: Indirect evidence (prevalence of variant in the population: *)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes, After publication
Data accessibility: Correspondence: Tyler Wagner (tyler@nference.net), Venky Soundararajan (venky@nference.net)
General comment Some concerns about uncontrolled confounding.